Drug Approval | July 10, 2024
Lupin receives tentative approval from USFDA for Empagliflozin, Linagliptin and Metformin Hydrochloride ER tablets
This product will be manufactured at Lupin’s Pithampur facility in India
This product will be manufactured at Lupin’s Pithampur facility in India
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
AAT is a substantial socio-economic burden to livestock farmers in Sub-Saharan Africa, affecting and killing millions of cattle every year
Lupin actively contributes to alleviating the burden of COPD for patients across the nation
This product will be manufactured at Lupin's Pithampur facility in India
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
The current ruling will assure the safety of the use of Ranitidine for Indian patients
Subscribe To Our Newsletter & Stay Updated
